HC Wainwright Issues Positive Outlook for DNTH Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Equities research analysts at HC Wainwright boosted their Q3 2026 earnings per share estimates for shares of Dianthus Therapeutics in a research note issued on Thursday, August 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($1.00) per share for the quarter, up from their previous forecast of ($1.43). HC Wainwright currently has a “Buy” rating and a $158.00 price target on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($3.83) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2026 earnings at ($1.11) EPS, FY2026 earnings at ($3.87) EPS, Q1 2027 earnings at ($1.26) EPS, Q2 2027 earnings at ($1.39) EPS, Q3 2027 earnings at ($1.51) EPS, Q4 2027 earnings at ($1.62) EPS, FY2027 earnings at ($5.77) EPS, FY2028 earnings at ($7.60) EPS, FY2029 earnings at ($0.13) EPS and FY2030 earnings at $10.75 EPS.

Several other equities analysts have also issued reports on the company. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Raymond James Financial restated a “strong-buy” rating and set a $131.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wedbush lifted their target price on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Finally, Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $124.27.

Dianthus Therapeutics Trading Down 3.0%

NASDAQ DNTH opened at $108.49 on Monday. Dianthus Therapeutics has a 12 month low of $19.00 and a 12 month high of $114.55. The stock has a market cap of $5.93 billion, a P/E ratio of -26.14 and a beta of 1.22. The stock’s fifty day moving average price is $95.71 and its 200-day moving average price is $81.79.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million.

Insider Activity

In related news, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the sale, the executive vice president directly owned 31,249 shares of the company’s stock, valued at $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Anne Mcgeorge sold 7,750 shares of Dianthus Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the sale, the director owned 1,250 shares of the company’s stock, valued at $136,262.50. The trade was a 86.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 284,306 shares of company stock valued at $29,289,369. Corporate insiders own 3.02% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $27,000. First Horizon Corp purchased a new stake in Dianthus Therapeutics in the first quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd bought a new stake in Dianthus Therapeutics in the 4th quarter worth approximately $40,000. Russell Investments Group Ltd. bought a new stake in Dianthus Therapeutics in the 3rd quarter worth approximately $64,000. Finally, Tower Research Capital LLC TRC grew its position in Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after purchasing an additional 3,317 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Key Stories Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright issued an optimistic estimate for Dianthus Therapeutics’ earnings, offering a potential bullish catalyst for DNTH. However, the report did not provide specific revised earnings targets. HC Wainwright Issues Optimistic Estimate for DNTH Earnings
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior reporting period, with a days-to-cover ratio of zero. This indicates little evidence of active short-selling pressure or a potential short squeeze in DNTH.
• Negative Sentiment: Several insiders sold shares around $109 to $111. Senior Vice President Adam M. Veness sold 20,000 shares across transactions on August 7 and August 10 for approximately $2.21 million, reducing his position by roughly 80.8% overall. SEC insider trading filing
• Negative Sentiment: Director Simon Read sold 2,777 shares for about $304,000, cutting his holdings by 50%. Director Anne McGeorge sold 7,750 shares for approximately $845,000, reducing her position by about 86%. The timing and size of these sales could raise concerns because they occurred while the stock was trading near its 12-month high. SEC director trading filing

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.